Coates LC, Orbai AM, Azevedo VF, Cappelleri JC, Steinberg K, Lippe R, et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health Qual Life Outcomes. 2020;18(1):173.

Article  PubMed  PubMed Central  Google Scholar 

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):2095–6.

PubMed  Google Scholar 

Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–65 (e19).

Article  PubMed  Google Scholar 

Romero Perez A, Queiro R, Seoane-Mato D, Graell E, Chamizo E, Chaves Chaparro L, et al. Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study. PLoS One. 2020;15(6): e0234556.

Article  PubMed  PubMed Central  Google Scholar 

Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–84.

Article  PubMed  Google Scholar 

Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5–32.

Article  PubMed  Google Scholar 

Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465–79.

Article  PubMed  PubMed Central  Google Scholar 

Queiro R, Loredo M, Brana I, Pardo E, Alonso S, Alperi M. Managing psoriatic arthritis in different clinical scenarios. Expert Rev Clin Immunol. 2023;19(12):1469–84.

Article  PubMed  Google Scholar 

Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706–19.

Article  PubMed  Google Scholar 

Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: a literature review. Best Pract Res Clin Rheumatol. 2021;35(2): 101692.

Article  PubMed  Google Scholar 

Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, Kok MR, Tchetverikov I, Korswagen LA, et al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024;10(1):e004062.

Hen O, Harrison SR, De Marco G, Marzo-Ortega H. Early psoriatic arthritis: when is the right time to start advanced therapy? Ther Adv Musculoskelet Dis. 2024;16:1759720X241266727.

Article  PubMed  PubMed Central  Google Scholar 

Caso F, Costa L, Megna M, Cascone M, Maione F, Giacomelli R, et al. Early psoriatic arthritis: clinical and therapeutic challenges. Expert Opin Investig Drugs. 2024;7:1–21.

Google Scholar 

Loredo M, Brana I, Queiro R. Does pharmacological intervention prevent or delay the onset of psoriatic arthritis among psoriasis patients? Expert Opin Biol Ther. 2023;23(12):1159–62.

Article  PubMed  Google Scholar 

Pennington SR, FitzGerald O. Early origins of psoriatic arthritis: clinical, genetic and molecular biomarkers of progression from psoriasis to psoriatic arthritis. Front Med (Lausanne). 2021;8: 723944.

Article  PubMed  PubMed Central  Google Scholar 

Paine A, Brookes PS, Bhattacharya S, Li D, De La Luz G-H, Tausk F, Ritchlin C. Dysregulation of bile acids, lipids, and nucleotides in psoriatic arthritis revealed by unbiased profiling of serum metabolites. Arthritis Rheumatol. 2023;75(1):53–63.

Article  PubMed  Google Scholar 

Lopez-Medina C, McGonagle D, Gossec L. Subclinical psoriatic arthritis and disease interception-where are we in 2024? Rheumatology (Oxford). 2025;64(1):56–64.

Article  PubMed  Google Scholar 

Haberman RH, MacFarlane KA, Catron S, Samuels J, Blank RB, Toprover M, et al. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ Open. 2022;12(12): e063650.

Article  PubMed  PubMed Central  Google Scholar 

Perez-Chada LM, Haberman RH, Chandran V, Rosen CF, Ritchlin C, Eder L, et al. Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. Nat Rev Rheumatol. 2021;17(4):238–43.

Article  PubMed  PubMed Central  Google Scholar 

Zabotti A, De Marco G, Gossec L, Baraliakos X, Aletaha D, Iagnocco A, et al. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis. 2023; 82(9):1162–70.

Watson L, Coyle C, Whately-Smith C, Brooke M, Kiltz U, Lubrano E, et al. An international multi-centre analysis of current prescribing practices and shared decision-making in psoriatic arthritis. Rheumatology (Oxford). 2023. https://doi.org/10.1093/rheumatology/kead621.

Article  PubMed  Google Scholar 

Coates L, Gossec L. The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences. Joint Bone Spine. 2022;90(1): 105469.

Article  PubMed  Google Scholar 

Brown MA, Rudwaleit M, van Gaalen FA, Haroon N, Gensler LS, Fleurinck C, et al. Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Ann Rheum Dis. 2024. https://doi.org/10.1093/rheumatology/keae163.202.

Article  PubMed  Google Scholar 

Coates LC, de Wit M, Buchanan-Hughes A, Smulders M, Sheahan A, Ogdie AR. Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: a systematic review of real-world evidence. Rheumatol Ther. 2022;9(3):803–21.

Article  PubMed  PubMed Central  Google Scholar 

Richette P, Coates LC, Azevedo VF, Cappelleri JC, Moser J, Queiro-Silva R, et al. Patient perception of medical care for psoriatic arthritis in North America and Europe: results from a global patient survey. Rheumatol Ther. 2022;9(3):823–38.

Article  PubMed  PubMed Central  Google Scholar 

Garcia-Vicuna R, Garrido N, Gomez S, Joven B, Queiro R, Ramirez J, et al. Management of particular clinical situations in psoriatic arthritis: an expert’s recommendation document based on systematic literature review and extended Delphi process. Rheumatol Int. 2021;41(9):1549–65.

Article  PubMed  PubMed Central  Google Scholar 

Queiro R, Lorenzo A, Tejon P, Coto P, Pardo E. Obesity in psoriatic arthritis: comparative prevalence and associated factors. Medicine (Baltimore). 2019;98(28): e16400.

Article  PubMed  Google Scholar 

Gelfand JM, Wan J, Zhang H, Shin DB, Ogdie A, Syed MN, Egeberg A. Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: a population-based study. J Am Acad Dermatol. 2021;84(6):1636–43.

Article  PubMed  Google Scholar 

Klingberg E, Bjorkman S, Eliasson B, Larsson I, Bilberg A. Weight loss is associated with sustained improvement of disease activity and cardiovascular risk factors in patients with psoriatic arthritis and obesity: a prospective intervention study with two years of follow-up. Arthritis Res Ther. 2020;22(1):254.

Article  PubMed  PubMed Central  Google Scholar 

Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE. 2018;13(5): e0195123.

Article  PubMed  PubMed Central  Google Scholar 

Pantano I, Iacono D, Favalli EG, Scalise G, Costa L, Caso F, et al. Secukinumab efficacy in patients with PsA is not dependent on patients’ body mass index. Ann Rheum Dis. 2022;81(3): e42.

Article  PubMed  Google Scholar 

Alonso S, Villa I, Fernandez S, Martin JL, Charca L, Pino M, et al. Multicenter study of secukinumab survival and safety in spondyloarthritis and psoriatic arthritis: SEcukinumab in Cantabria and ASTURias Study. Front Med (Lausanne). 2021;8: 679009.

Article  PubMed  PubMed Central  Google Scholar 

Queiro R. Cardiometabolic comorbidity in the selection of treatment in spondyloarthritis: one step closer to truly personalized medicine? Expert Opin Biol Ther. 2021;21(12):1539–41.

Article  PubMed  Google Scholar 

Hojgaard P, Glintborg B, Hetland ML, Hansen TH, Lage-Hansen PR, Petersen MH, et al. Association between tobacco smoking and response to tumour necrosis factor alpha inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis. 2015;74(12):2130–6.

Article